2 Under-the-Radar Biotech Stocks to Buy in 2022

·4 min read
2 Under-the-Radar Biotech Stocks to Buy in 2022

With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM). Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting